Form 4: Halozyme COO Gains Equity Awards, Boosting Alignment

Halozyme Therapeutics' Chief Operating Officer, Cortney Caudill, received significant equity awards including stock options, restricted stock units, and performance stock units.

Summary

• Cortney Caudill, SVP, Chief Operating Officer of Halozyme Therapeutics, Inc. (HALO), reported the acquisition of various equity awards on February 9, 2026.
• Awards include 14,047 shares from an option to purchase common stock at an exercise price of $80.48, which vests one-fourth on February 9, 2027, and then 1/48th monthly thereafter, expiring on February 9, 2036.
• Also received 13,047 Restricted Stock Units (RSUs) with a $0 exercise price, vesting one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
• Additionally, 2,403 Performance Stock Units (PSUs) from a February 23, 2024 grant and 14,751 PSUs from a February 20, 2025 grant were determined eligible to vest based on performance through December 31, 2025, both with a $0 exercise price and subject to further service-based vesting through the third anniversary of their respective grant dates.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and positive development for corporate governance, as it aligns executive incentives with shareholder interests, reflecting standard compensation practices and the achievement of prior performance targets for PSUs.

Positives

• The equity grants align management incentives with shareholder interests, encouraging long-term commitment from a key executive.
• The determination of eligible Performance Stock Units indicates the achievement of prior performance targets set by the company.

Future Outlook

The vesting schedules for the options, Restricted Stock Units (RSUs), and Performance Stock Units (PSUs) extend into future years, indicating continued executive retention and alignment with long-term company performance. The option vests one-fourth on February 9, 2027, then 1/48th monthly thereafter, expiring on February 9, 2036. RSUs vest one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. PSUs are subject to a service-based requirement through the third anniversary of their respective grant dates.

Industry Context

StockSavvy.ai notes that executive equity grants are a standard practice in the biotechnology and pharmaceutical industries, serving to incentivize leadership and align their financial interests with long-term shareholder value creation. The mix of options, RSUs, and performance-based units is typical for executive compensation packages, reflecting a balanced approach to retention and performance incentives.

Comparison to Industry Standards

• Executive compensation packages in the biotech sector often include a significant equity component, typically comprising a mix of stock options, restricted stock units (RSUs), and performance stock units (PSUs).
• For example, companies like Amgen (AMGN) and Gilead Sciences (GILD) frequently grant similar equity awards to their senior executives, with vesting schedules designed to promote long-term commitment and performance.
• The specific number of units granted to Cortney Caudill appears to be within the expected range for a Chief Operating Officer at a company of Halozyme's size and market capitalization, though a direct comparison would require detailed analysis of peer group compensation data.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term shareholder value. Dilution from new shares issued upon vesting is a consideration, but this is standard for equity compensation.
• Management: Increased incentive for long-term performance and retention of a key executive.

Next Steps

• Continued service by Cortney Caudill to meet vesting requirements for equity awards.
• Future vesting events for options, RSUs, and PSUs on their respective schedules.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While it indicates continued executive alignment and past performance achievement for PSUs, it does not present new information that would fundamentally alter the investment thesis for Halozyme Therapeutics. Investors should continue to hold based on broader company fundamentals and market conditions, as this filing alone does not warrant a change in recommendation.

Keywords

Halozyme Therapeutics, HALO, Cortney Caudill, Insider Transaction, Equity Award, Stock Option, Restricted Stock Units, Performance Stock Units, Executive Compensation, SVP Chief Operating Officer